Department of Dermatology, Mayo Clinic/Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
Dermatol Ther. 2010 May-Jun;23(3):268-80. doi: 10.1111/j.1529-8019.2010.01323.x.
Mucous membrane pemphigoid and pemphigus vulgaris are autoimmune blistering disorders in which many similar drugs and therapeutic strategies are utilized. In general, localized disease can be treated with topical agents. In contrast, patients with more severe and progressive disease usually require a combination of systemic corticosteroids and immunosuppressive medications. Oral corticosteroids, adjuvant immunosuppressive agents, antibiotics such as dapsone and immunomodulatory procedures like intravenous immunoglobulin are the main therapeutic agents used in treating these two disorders. Much of the morbidity and mortality associated with these disorders are related to the sites involved and to the drugs used for therapy. Treatment should be individualized based on severity, extent, and rate of progression of disease, comorbidities, and age of the patient. Serum levels of specific autoantibodies and indirect immunofluorescence titers, in certain cases, can be used to monitor response to therapy.
黏膜类天疱疮和寻常型天疱疮是自身免疫性水疱病，其中许多类似的药物和治疗策略被用于治疗。一般来说，局限性疾病可以用局部药物治疗。相比之下，病情更严重和进展性的患者通常需要全身皮质类固醇和免疫抑制药物的联合治疗。口服皮质类固醇、辅助免疫抑制剂、氨苯砜等抗生素和静脉注射免疫球蛋白等免疫调节程序是治疗这两种疾病的主要治疗药物。这些疾病相关的发病率和死亡率主要与受累部位以及治疗中使用的药物有关。治疗应根据疾病的严重程度、范围、进展速度、合并症和患者年龄进行个体化。在某些情况下，可以使用特定自身抗体的血清水平和间接免疫荧光滴度来监测对治疗的反应。
